What is he best known for?
The fields of study he is best known for:
Tzyy Choou Wu mainly focuses on Antigen, Virology, DNA vaccination, CD8 and Immunology.
His studies in Antigen integrate themes in fields like Vaccinia, Immune system, Antigen presentation and Cancer research.
The various areas that he examines in his Virology study include Antigen Gene, Replicon and Vaccine Potency.
His study looks at the relationship between DNA vaccination and topics such as Potency, which overlap with Recombinant DNA.
His studies deal with areas such as Molecular biology and Immunotherapy, Cancer immunotherapy as well as CD8.
He has included themes like Lesion, Cervical intraepithelial neoplasia, In vivo and Confidence interval in his Immunology study.
His most cited work include:
- Treatment of Established Tumors with a Novel Vaccine That Enhances Major Histocompatibility Class II Presentation of Tumor Antigen (889 citations)
- Obesity induces expression of uncoupling protein-2 in hepatocytes and promotes liver ATP depletion. (390 citations)
- Enhancement of DNA vaccine potency by linkage of antigen gene to an HSP70 gene. (351 citations)
What are the main themes of his work throughout his whole career to date?
Immune system, Immunology, Antigen, DNA vaccination and Virology are his primary areas of study.
His Immune system study combines topics from a wide range of disciplines, such as Cytotoxic T cell and Cancer research.
His study in Immunology is interdisciplinary in nature, drawing from both Cervical cancer and HPV vaccines.
His Antigen research integrates issues from Molecular biology, Naked DNA and Antigen presentation.
His DNA vaccination research includes elements of Genetic enhancement, Transfection and Immunogenicity.
His Virology research is multidisciplinary, incorporating elements of Vaccinia and Replicon.
He most often published in these fields:
- Immune system (36.49%)
- Immunology (36.49%)
- Antigen (32.88%)
What were the highlights of his more recent work (between 2014-2021)?
- Cancer research (22.07%)
- Immune system (36.49%)
- DNA vaccination (30.18%)
In recent papers he was focusing on the following fields of study:
His primary scientific interests are in Cancer research, Immune system, DNA vaccination, Cancer and Immunology.
His biological study spans a wide range of topics, including Cytotoxic T cell, Prospective cohort study, Biopsy and Antigen.
His research in Antigen intersects with topics in Antibody, Combination therapy and Capsid.
His DNA vaccination research is multidisciplinary, incorporating elements of T cell, Calreticulin and Virology, Vaccination.
His Cancer research includes elements of Oncology and Ascites.
His Immunology research includes themes of HPV vaccines and Papillomavirus Vaccines.
Between 2014 and 2021, his most popular works were:
- Perspectives for therapeutic HPV vaccine development (82 citations)
- Immunotherapy for human papillomavirus-associated disease and cervical cancer: review of clinical and translational research (58 citations)
- A pilot study of pNGVL4a-CRT/E7(detox) for the treatment of patients with HPV16 + cervical intraepithelial neoplasia 2/3 (CIN2/3) (58 citations)
In his most recent research, the most cited papers focused on:
Tzyy Choou Wu mostly deals with Immunology, Cervical cancer, Cancer, Human papillomavirus and HPV vaccines.
His Immunology research integrates issues from Pharmacology and In vivo.
His research integrates issues of Radiation therapy, Chemotherapy, Reprogramming, Cytotoxic T cell and Epigenetics in his study of Cancer.
Tzyy Choou Wu combines subjects such as Virology, Hpv types, Therapeutic vaccine, DNA vaccination and Uterine cervix with his study of Human papillomavirus.
His HPV vaccines study combines topics from a wide range of disciplines, such as Clinical trial, Cervix, Cervarix, Gardasil and Papillomavirus Vaccines.
His Papillomavirus Vaccines research incorporates elements of Oncology, HPV infection and Vaccination.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
